RECENT AND UPCOMING MILESTONES

Lots of good details can be found on their website: Cel-Sci.com.  But the best recap is their Corporate Presentation. 

-SEEKINGALPHA-

Probably the most accurate and concise articles written are:

• Setting The Record Straight on Cel-Sci
• On the Verge of Approval
• Learning From Bristol-Myers' Ipilimumab

Review all the Articles and Blogs from our 2 Authors:

• Fosco Research
• North Shore Research

-ZACKS-

Zacks is providing "paid coverage".  Various reports here from them:

• October IDMC Report with Increase in Price Target: ZACKS IDMC
• 3rd Quarter's Update: ZACKS 3Q
• Initiation: ZACKS.  

Delays are never good, right? Here is the thing...  The trial ends when the 298th event (death) happens.  But people aren't dying as fast as statistics would suggest for survival of Head and Neck cancer patients.  Why?  We believe its Multikine.  The most recent Corporate Presentation 10/25 noted that the 298 event hasn't occurred.  

On 10/15/19, it was announced that the IDMC reviewed the UNBLINDED data for efficacy, safety and FUTILITY.  Their recommendation: Continue the trail until the last event! Details HERE

Need more proof and you're a Stats Junkie?  Then head on over to the Google Sheets created by our "National Treasure" FOSCO and team from the iHub message boards.  These sheets estimate that we are now past 10% of Standard Care.  

• On 6/18, this Conference video came out: Video
• On 5/16, a new interview came out: Video
• On 5/8, Geert issued a Press Release: Shareholder Letter
• Geert did an interview 5/2/19: ThinkEquity Interview 

REVERSE SPLITS is the latest SHORT tactic!  Yes, we have had 3 Reverse Splits. But that was then due to low share price.  Did you know a Reverse Split REQUIRES Shareholder approval? Its true. This approval request is done via a Proxy. Here is the latest Proxy: 

PROXY

****DID YOU SEE ANY REQUEST FOR AN APPROVAL OF A REVERSE SPLIT!?***

Furthermore, why would we do a Reverse Split now that we are at $5.00?  Are we at threat to be delisted?  No!  Here is why companies do Reverse Splits: 

REVERSE SPLIT INFO

 This is always an issue with Biotechs.  Constant financing.  Dilution.  Wash, Rinse, Repeat.

The last 10Q as of 6/30/19 stated they have over $12M of cash.  No offering until April 2020!

Visit  Cash Page for current details

Really?  We currently have a $295M (as of 7/2/19) Market Cap and a share price over $8.00.  Do some due diligence.  Upon a successful read out of the Phase III data, we are talking Billions and Billions!  I wont give you share price expectations, but what I will give you is recent buyouts of other bios:

•   Eli Lilly bought Loxo Oncology for about $8 billion.  Just $8 billion.
•  https://www.fool.com/investing/2018/07/05/3-best-biotech-acquisitions-of-2018-so-far.aspx 
•  https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_mergers_and_acquisitions 
• Google the stock BPTH.  Phase 2 Biotech.  Take a look what happened there in just 1 day.

Do the math!  We are at $295M with about 33M shares outstanding....How does one get to a $5B-$10B. Market Cap...?  The multiples are insane, but its possible!

Bashers Bash.  See why here: https://messageboardfools.com/bashers.htm 

They will say anything to make your give up your shares.  Stay long!